ICM-2021 | Osaka, Japan

Stage 1: Keynote Forum -Strategic Thinkers for Next Generation Medichem
Part 1: Opening Ceremony	Part 3: Master Dialogs of GALATECH
Part 2: GALATECH Plenary Summit • Speech from WHO • Speech from Health Ministrial Officers • Speech from Those Entrepreneur Leaders Changing the World Health Status • Speech from Top 10 World Class University President • Speech from Top Healthcare Industries • Speech from Top Biotech Industries • Speech from Global Prize Laureates	Part 4: Keynote Forum of ICM-2021 • Disruptive Technologies in Medichem • Emerging Drug Targets Discovery • New Drug Chemical Modalities Discovery • Smart Drug Design • Preclinical Process • Next Generation Drug Pipeline • Integrative Discovery Chemistry Services
Stage 2: New Era of Medichem Methodology Disruptions -Strategic Innovators Enable Early Drug Discovery
Xlab 01: AI in Medicinal Chemistry	Xlab 09: Navigating Chemical and Druggable Space
Xlab 02: Big Data and ML/DL for Discovery Chemistry	Xlab 10: DNA-Encoded Library (DEL) Technology
Xlab 03: VR/AR/MR for Drug Design	Xlab 11: Chemical Discovery in the Era of Metabolomics
Xlab 04: Predictive Medicinal Chemistry	Xlab 12: Enzyme Direct Evolution and Biotransformations in Medichem
Xlab 05: Internet of Chemistry in Drug Discovery	Xlab 13: New Approaches to Drug Candidate Optimization and Characterization
Xlab 06: Robotics and Automations in Medicinal Chemistry	Xlab 14: Emerging Medichem in silico
Xlab 07: CRISPR/Cas9 and Genome Editing	Xlab 15: Generative Recurrent Networks for De Novo Drug Design
Xlab 08: Virtual Hit-to-Lead Optimization	Xlab 16: Cheminformatics and Bioinformatics in Medichem
Stage 3: Pioneerscape of Target Druggability -Leadership in Discovering Validated Targets
Theme 1: Targets Validation and Discovery
Family 1-1: New Strategies and Platforms for Evaluating New Drug Targets	Family 1-6: Cell Biology Methods in Target Validation
Family 1-2: Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine	Family 1-7: Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery
Family 1-3: Affinity-Based Chemoproteomics for Target Identification	Family 1-8: Genetic Manipulation/Modulation for Target Discovery and Validation
Family 1-4: Elucidating Target Biology and Drug Mechanism of Action Across Human Cell-Based Model Systems	Family 1-9: Label-Free Techniques for Target Discovery and Validation
Family 1-5: Activity-Based Protein Profiling	Family 1-10: Bioinformatic Approaches in the Understanding of Mechanism of Action
Theme 2: Targeting DNA/Gene, RNA and Nuclear Receptors
Family 2-1: CRISPR/Cas9 & Targeted Genome Editing	Family 2-4: Targeting Oligonucleotides
Family 2-2: Targeting miRNA，siRNA and other ncRNA	Family 2-5: Epigenetic Targets
Family 2-3: Targeting DNA/Gene and DNA-DNA Interactions	Family 2-6: Targeting Nuclear Receptors
Theme 3: Targeting Proteins, Emerging Receptors and Enzymes
Family 3-1: Targeting the Unfolded Protein Response	Family 3-5: Targeting Membrane Protein
Family 3-2: Challenging Kinases and Phosphatase -PI3K, PTP, SHP-2, PTP2C, PSTPS, PP2A and PP2B	Family 3-6: Targeting Histone Methyltransferases
Family 3-3: Disordered Proteins as Drug Targets	Family 3-7: Targeting Emerging Receptors
Family 3-4: Targeting Metabolic Enzyme	Family 3-8: Targeting CDC25 Phosphatases
Theme 4: Targeting Protein-Protein Interactions (PPIs) and Protein-DNA Interactions
Family 4-1: Advances in Targeting PPIs	Family 4-4: PPI Inhibitors
Family 4-2: PPI Modeling and Drug Screening	Family 4-5: Targeting Protein-Nucleic Acid Complexes
Family 4-3: PPI Modulators/Regulators	Family 4-6: Science and Tech in Exploring PPI
Theme 5: Targeting Protein Degradation and PROTAC
Family 5-1: Small Molecule Degraders	Family 5-6: Target the Autophagy/Lysosome Pathway
Family 5-2: Novel PROTACs Design	Family 5-7: ‘Molecular glue’ Degrader
Family 5-3: Druggable Proteome	Family 5-8: Genetic Fusion Strategies of Degradation Tags For Targeted Protein Degradation and The dTAG system
Family 5-4 Novel Ligases & Chaperones for Degradation	Family 5-9: Macromolecular conjugates as Protein Degrader
Family 5-5: Bifunctional Degrader	Family 5-10: Protein Degradation Discovery Toolbox
Theme 6: Targeting GPCR and Ion Channels
Family 6-1: GPCR-Allosteric Modulation	Family 6-5: GPCR Signaling Complexities
Family 6-2: Non-Classical Signaling	Family 6-7: Biased GPCR Signaling
Family 6-3: Engaging GPCRs	Family 6-6: Emerging Technologies for Targeting, Assaying and Modulating Ion Channel Targets
Family 6-4: Opioid Receptors	Family 6-8: Ion Channels as Therapeutic Antibody Targets
Theme 7: Druggable IO Targets
Family 7-1: Frontier of IO Targets	Family 7-4: Targeted IO Therapies
Family 7-2: Immunomodulator Targets	Family 7-5: Oncolytic Virus Targets in IO
Family 7-3: Cancer Vaccine Targets	Family 7-6: IO Cell Therapy and Bispecific Antibody Targets
Theme 8: Drugging Undruggable Targets -Meet the Challenges in Difficult Targets
Family 8-1: Drugging Undruggable Molecular Cancer Targets	Family 8-4: RAS and KRAS
Family 8-2: Drugging “Undruggable” Genes	Family 8-5: Targeting Resistant Targets
Family 8-3: Transcription factors (TFs)	Family 8-6: Other Challenging Targets for Drug Design
Theme 9: Next Wave of Epigenetic-Targeting Drug Discovery -New Dreamland of Medicinal Chemists
Family 9-1: Selecting Ideal Epi-Targets for Hackling	Family 9-5: Preclinical In-Vivo Biology of Epi-drugs
Family 9-2: Epi-Biomarker Discovery	Family 9-6: Advanced Tools -New Challenges from Crispr and Genome Editing
Family 9-3: Epi-Drug Design and Synthesis	Family 9-7: Pharmacology of Epi-drugs
Family 9-4: Enzymatic Assay and In Vitro Studies of Epi-Drugs	Family 9-8: Clinical Trials of Epi-drugs
Theme 10: Targeting Microbiota -New Frontier of System Chemical Biology
Family 10-1: Microbiome and Microbiota Science	Family 10-5: Microbiome Discovery Goes Small Molecules
Family 10-2: The Microbiome Drug Discovery	Family 10-6: Microbiome Metabolite Mimics
Family 10-3: Microbiome as a Target for Cancer Therapy	Family 10-7: Microbiota Toxin and Anti-Toxin Development
Family 10-4: Advanced Microbiome Biotech	Family 10-8: Microbiome Drug Clinical Trials
Stage 4: New Shapers of Drug Chemical Modalities -Booming Achievements in Discovery New Chemical Diversities
Art Show 01: Oligonucleotides, ASOs & RNAi	Art Show 07: Peptibody
Art Show 02: Next generation Peptides and Peptidomimetics	Art Show 08: Protein Degraders
Art Show 03: Current Mixed Drug Modalities	Art Show 09: Targeted Covalent Inhibitors (TCIs)
Art Show 04: Small Molecule-Drug Conjugates (SMDCs)	Art Show 10: Fusion Protein and BiTE® Antibody Construct
Art Show 05: Molecular Conjugates for Targeted Delivery	Art Show 11: Chemical Probes for Characterizing Biology
Art Show 06: RNAi, miRNA-Based Modality Therapeutics	Art Show 12: Bioimaging
Stage 5: Drug Design Artists -Intelligent Creation of Potential Hit to Leads
Art Show 01: Fragment Based Drug Design	Art Show 10: In Vivo Imaging in Drug Design
Art Show 02: Structure/Biostructure-based and ligand-based drug Design	Art Show 11: Systems Biology in Drug Design -From Drug-Target Space (off-target), Systems Biology Space to Phenotype Space
Art Show 03: Novel Approaches in Silico Drug Design	Art Show 12: New Chiral Drug Design
Art Show 04: Ligand-Based Drug Design	Art Show 13: Multi-Target Drug Design
Art Show 05: Design based on Drug-Like Properties and Decision Making	Art Show 14: Rational Receptors-based Drug Design
Art Show 06: Chemical Biology and Structural Biology in Drug Design	Art Show 15: Design of an Effective Natural-Products-Based Approach
Art Show 07: Design of Hybrid Molecules	Art Show 16: Prodrug-based Drug Design and Development
Art Show 08: Macrocycles in Drug Design	Art Show 17: Mechanism and Pathway based Drug Design
Art Show 09: Design Long Lasting, Oral Bioavailability and Brain Penetration	Art Show 18: Selective Optimization of Side Activities (SOSA) in Drug Discovery
Stage 6: Masters of New Discovery Synthetic Toolbox -Robust Chemistry toward Desired Candidates
SynTech 01: Molecular Conjugates for Targeted Delivery	SynTech 14: Chemistry of Biomarkers
SynTech 02: Discovery Click Chemistry for Drug Conjugates	SynTech 15: TCM and Natural Products Drug Chemistry
SynTech 03: Antibody-Recruiting Small Molecules Constructs as Immunotherapeutics	SynTech 16: Biomaterial/Biopolymer Chemistry in Drug Discovery
SynTech 04: Nucleic Acids Drugs Chemistry	SynTech 17: Natural Product Discovery and Biosynthesis
SynTech 05: Fusion Peptide and Protein	SynTech 18: Enantioselective Organocatalysis in Medichem
SynTech 06: Medichem for Better Protein Drugs	SynTech 19: Continuous Flow Chemistry in Medicinal Chemistry
SynTech 07: Medichem for Antibody-Drug Conjugates	SynTech 20: Medicinal Organometallic Chemistry
SynTech 08: Vaccine Medicinal Chemistry	SynTech 21: Diversity-Oriented Synthesis
SynTech 09: Synthetic Biology in Medicinal Chemistry	SynTech 22: Biosynthesis to Construct Complex Molecules
SynTech 10: Template Guided Systems	SynTech 23: New Catalysis in Medicinal Chemistry
SynTech 11: Art of Total Synthesis	SynTech 24: Isotope labeling Chemistry for Drug Discovery
SynTech 12: Carbohydrate-based Medicinal Chemistry	SynTech 25: Heterocycles in Medicinal Chemistry
SynTech 13: Solid Phase and Combinatorial Chemistry	SynTech 26: Structure-biodegradability Relationship
Stage 7: Accelerators of Bio/Physical Testing -Shortening the Preclinical Process
Platform 01: Innovative Drug Screening	Platform 05: Chemical, Bio/Physical Tools for Early Clinical Trials
Platform 02: HT Chemistry for Hit and Lead Synthesis	Platform 06: Target Deconvolution, Validation and Target Discovery
Platform 03: Microfluidics, Mesofluidics, and Lab-on-a-chip Technologies	Platform 07: Predictive Toxicology in Drug Safety
Platform 04: New Drug Discovery Screening Cascades -In Vitro, Ex-Vivo, and In Vivo	Platform 08: Drug Efficacy Evaluation
Stage 8: Integrative Discovery Chemistry Servers -Future of CRO, CSO, CMO, CXO
Platform 01: Discovery Process Services -Target Selection, Validation, and Lead Optimization	Platform 05: Small Molecule Discovery Services
Platform 02: ADMEX and DMPK Services	Platform 06: Clinical Trial Services
Platform 03: Medicinal Chemistry -Drug Candidate In Vitro and In Vivo Evaluations	Platform 07: Biotherapy R & D Services
Platform 04: CMO Services of GLP and GMP Synthesis	Platform 08: CMC Regulatory Affair Services
Stage 9: Smart Inventors Hackling Unmet Diseases -Pipeline Briefing on Next $Billion Solutions to Unsolved Man’s Disorders
Hub 01: Small Molecule Immuno-Oncology	Hub 09: Pain & Addiction
Hub 02: Targeting Anticancer Drugs	Hub 10: Blood and Blood Organ Generation Diseases
Hub 03: Novel Cardiovascular Drugs	Hub 11: Inflammatory and Immune Diseases
Hub 04: CNS Diseases and Pain	Hub 12: Bone Diseases
Hub 05: GI, Liver and Disorders	Hub 13: Skin Disorders
Hub 06: New Antivirals and Challenging Antibacterials -Hackling Emerging Infections and Drug Resistance	Hub 14: Genito Urinary and Regeneration Organ Diseases
Hub 07: Anti-Aging Drugs Diabetes & Obese	Hub 15: Metabolic and Hormone Disorders
Hub 08: Respiratory Diseases	Hub 16: Rare Diseases
Stage 10: Futurists of Discovery Chemistry -Young Chemists’ Short Talk and Poster Sessions
Nexus 1: Innovation in Target Discovery	Nexus 4: Drug Screening and Hit-to-Lead Optimization
Nexus 2: AI/ML/DL in Medicinal Chemistry	Nexus 5: Smart Drug Characterization Technology for Candidates
Nexus 3: ADMET/PKPD of Biotherapy	Nexus 6: Green Medichem/Pharmaceutical Process Chemistry
Stage 11: Women Experts in Medichem -Making Medichem World Family Diversified
Forum 01: Women Leadership in Medicinal Chemistry	Forum 03: Women’s Creativity in Drug Design
Forum 02: Women’s Innovations in Medichem	Forum 04: Women’s Innovative Chemistry
Stage 12: Great Mentors of New Concepts in Medichem -Knowledge Drives to Success
Workshop 01: Chemical Biology & Medicinal Chemistry	Workshop 07: Robotics and Automations in Medichem
Workshop 02: Synthetic Biology in Medichem	Workshop 08: Continuous Flow Technology
Workshop 03: Quantum Chemistry in Medicinal Chemistry	Workshop 09: Biomolecular Medicinal Chemistry
Workshop 04: Bimolecular Simulations	Workshop 10: Small Molecules for Immuno-Oncology Therapeutics
Workshop 05: Retrometabolic Drug Design	Workshop 11: Precision Medicine and Medicinal Chemistry
Workshop 06: New Virtual Reality Tool for Structure-Based Drug Design	Workshop 12: New Synthetic Technologies in Medichem
Joint Conferences
Theme 1: Joint Satellite Clustering Meetings of IDDST-Japan 2021 Theme 2: Joint Satellite Clustering Meetings of SDDS-Japan 2021 Theme 3: Joint Satellite Clustering Meetings of IO-Japan 2021 Theme 4: Joint Satellite Clustering Meetings of GCC-Japan 2021 Theme 5: Joint Satellite Clustering Meetings of Synbio+-Japan 2021
S 4-1: When Entrepreneurs Meet with VCs	S 4-5: Project Matchmaking
S 4-2: BP Roadshow	S 4-6: PSA Onsite: 1 to 1/Face to Face Meetings
S 4-3: Industry Park Briefing	S 4-7: Meet Your Future Mentors
S 4-4: New Tech/Products News Release Conference	S 4-8: Talents Recruitment Fair
Posters and Exhibition
Zone 1: Poster Shows	Zone 2: New Technologies and Products Exhibition
Branding Building and Cultural Activities
Activity 1: Welcome Banquet and Award Ceremony	Activity 4: Field Trip to Parks
Activity 2: Industrial Sponsored Lunch Showcase and Cocktail Party	Activity 5: Japan Impression Tech-Tour
Activity 3: Master Tours to Campus	Activity 6: Closing and Signing Ceremony

	Abstract Format
	Sponsorship Opportunity
	Exhibition Application